{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:13:26Z","timestamp":1776928406003,"version":"3.51.2"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ad.2025.104522","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:48:59Z","timestamp":1764834539000},"page":"104522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review of Treatments for Cutaneous Chronic Graft-versus-Host Disease"],"prefix":"10.1016","volume":"117","author":[{"given":"M.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6723","authenticated-orcid":false,"given":"M.","family":"Mansilla-Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Fernandez-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104522_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2009.00577.x","article-title":"Many faces of graft-versus-host disease","volume":"51","author":"Pe\u00f1as","year":"2010","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2025.104522_bib0245","article-title":"Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease","volume":"18","author":"Novitzky-Basso","year":"2023","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ad.2025.104522_bib0250","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","article-title":"Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation","volume":"75","author":"Atkinson","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0255","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ad.2025.104522_bib0260","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0265","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","article-title":"Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation \u2013 results from a single-center observational study","volume":"22","author":"Grube","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0270","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0275","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104522_bib0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0295","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/blood-2012-10-464198","article-title":"Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0300","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.bbmt.2014.07.001","article-title":"Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"20","author":"Uhm","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0305","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamadermatol.2015.121","article-title":"Cutaneous malignant neoplasms in hematopoietic cell transplant recipients: a systematic review","volume":"151","author":"DePry","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2025.104522_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.01.012","article-title":"Role of graft-versus-host disease in the development of secondary skin cancers in hematopoietic stem cell transplant recipients: a meta-analysis","volume":"79","author":"Rambhia","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104522_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2011.11.961","article-title":"Graft-versus-host disease: Part I. Pathogenesis and clinical manifestations of graft-versus-host disease","volume":"66","author":"Hymes","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104522_bib0320","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bbmt.2013.01.013","article-title":"National Institutes of Health Chronic Graft-versus-Host Disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis","volume":"19","author":"Baird","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0325","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ad.2025.104522_bib0330","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.ad.2025.104522_bib0335","series-title":"Graft-versus-Host Disease: Pathogenesis and Treatment","author":"Mukai","year":"2018"},{"key":"10.1016\/j.ad.2025.104522_bib0340","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajd.12191","article-title":"Phototherapy for the treatment of cutaneous graft versus host disease","volume":"56","author":"Garbutcheon-Singh","year":"2015","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2025.104522_bib0345","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ad.2025.104522_bib0350","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ad.2025.104522_bib0355","series-title":"Covidence Systematic Review Software","year":"2024"},{"key":"10.1016\/j.ad.2025.104522_bib0360","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ad.2025.104522_bib0365","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ad.2025.104522_bib0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2025.104522_bib0375","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.ad.2025.104522_bib0380","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2023-182198","article-title":"Topical ruxolitinib for chronic cutaneous GvHD: promising results of a phase 2 clinical trial","volume":"142","author":"Markova","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0385","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2025.104522_bib0390","series-title":"Data From: Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD). United States, Canada, France, Germany, Spain, United Kingdom","year":"2018"},{"key":"10.1016\/j.ad.2025.104522_bib0395","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/bloodadvances.2019000145","article-title":"Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD","volume":"3","author":"Jagasia","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.ad.2025.104522_bib0400","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease","volume":"112","author":"Flowers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0405","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","article-title":"The role of janus kinase signaling in graft-versus-host disease and graft versus leukemia","volume":"24","author":"Schroeder","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0410","series-title":"Chronic Graft Versus Host Disease (cGVHD)","year":"2022"},{"key":"10.1016\/j.ad.2025.104522_bib0415","series-title":"Hematopoietic Cell Transplantation (HCT). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): US Comprehensive Cancer Network","year":"2024"},{"key":"10.1016\/j.ad.2025.104522_bib0420","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2012.09131.x","article-title":"Organ-specific management and supportive care in chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2025.104522_bib0425","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/2395-3977.172859","article-title":"Extracorporeal photopheresis for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"1","author":"Chen","year":"2015","journal-title":"Cancer Transl Med"},{"key":"10.1016\/j.ad.2025.104522_bib0430","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.blre.2023.101142","article-title":"A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease","volume":"63","author":"Fatoum","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.ad.2025.104522_bib0435","series-title":"FDA Approves Belumosudil for Chronic Graft-versus-Host Disease","year":"2021"},{"key":"10.1016\/j.ad.2025.104522_bib0440","series-title":"AusPAR: Belumosudil","year":"2022"},{"key":"10.1016\/j.ad.2025.104522_bib0445","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0450","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2025.104522_bib0455","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V128.22.507.507","article-title":"Final results of a randomized phase 2 trial evaluating lower-dose versus higher-dose pomalidomide as therapy for corticosteroid-refractory chronic Gvhd","volume":"128","author":"Curtis","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ad.2025.104522_bib0460","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1083-8791(00)70058-9","article-title":"Hydroxychloroquine for the treatment of chronic graft-versus-host disease","volume":"6","author":"Gilman","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0465","first-page":"S117","article-title":"MSC cavity injection boosts Th1 subset and has good response in extensive cGVHD patients: a prospective multicentre randomized controlled trial","volume":"3","author":"Zheng","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ad.2025.104522_bib0470","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","article-title":"A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801","volume":"103","author":"Carpenter","year":"2018","journal-title":"Haematologica"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:17:16Z","timestamp":1770470236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025007914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0001731025007914"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104522","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Treatments for Cutaneous Chronic Graft-versus-Host Disease","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104522"}}